A phase I study of gemcitabine  + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors

ConclusionsThe MTD/RPTD of GD is gemcitabine 1000  mg/m2 weekly for 3 of 4 weeks and dasatinib 50  mg PO BID. The clinical activity of GD seen in this study was modest, and does not support its further investigation in pancreatic cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research